Boichard, Amélie
Lippman, Scott M.
Kurzrock, Razelle
Funding for this research was provided by:
National Institutes of Health (NIH P30 CA023100)
Article History
Received: 1 September 2021
Accepted: 4 November 2021
First Online: 2 December 2021
Declarations
:
: Not applicable.
: Not applicable.
: RK receives research funding from Genentech, Merck Serono, Pfizer, Boehringer Ingelheim, TopAlliance, Takeda, Incyte, Debiopharm, Medimmune, Sequenom, Foundation Medicine, Konica Minolta, Grifols, Omniseq, and Guardant, as well as consultant and/or speaker fees and/or advisory board for X-Biotech, Neomed, Pfizer, Actuate Therapeutics, Roche, Turning Point Therapeutics, TD2/Volastra, Bicara Therapeutics, Inc., has an equity interest in IDbyDNA and CureMatch Inc, serves on the Board of CureMatch and CureMetrix, and is a co-founder of CureMatch. S.M.L. is a co-founder of io9 and member of Biological Dynamics scientific advisory board.